Tuesday - December 16, 2025
Nucala Receives Positive CHMP Opinion for Treatment of Chronic Obstructive Pulmonary Disease
December 13, 2025
LONDON, England, Dec. 13 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Dec. 12, 2025:

* * *

Nucala (mepolizumab) receives positive CHMP opinion for treatment of chronic obstructive pulmonary disease (COPD)

- Positive opinion based on MATINEE phase III trial showing significant reduction in COPD exacerbations versus placebo in addition to inhaled triple therapy

- Nucala is the only monthly b . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products